Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada
Authors:
- 1 September 2014
- journal article
- Published by LymphoSign Journal Limited Partnership in LymphoSign Journal
- Vol. 01 (01) , 27-37
Abstract
Introduction: For close to half a century immunoglobulin replacement therapy has been the main therapy for patients unable to produce functioning antibodies. To date, both subcutaneous (SC) and intravenous delivery methods have been successful at effectively and safely replacing immunoglobulin. Home intravenous and SC therapy programs have been established and have gained attention, but the true motivation and frequency of switching from traditional hospital-based treatment to these alternatives remains unknown. This study aims to determine the willingness of patients in Canada to switch to a home-based gammaglobulin treatment program by quantifying related experiences and preferences.Methods: A cohort of 169 patients in Ontario currently on hospital-based intravenous immunoglobulin (IVIG) replacement therapy (referral centers or community hospitals) were sent a 2.5 page survey consisting of 25 questions. Data were collected and statistically analyzed using Fisher, χ2, and McNemar tests, where P < 0.05 was considered statistically significant.Results: Ninety-one patients responded and most agreed to consider home therapy regardless of the administration route, based on recommendations from an immunologist (IVIG, P = 0.006; SC, P < 0.001). Patients preferred switching to home IVIG rather than to SC (P = 0.01), but their concerns regarding home healthcare costs were more prominent with IVIG (P = 0.01). The main concern with current intravenous therapy was the overall loss of time (P = 0.0001), whereas for home therapy it was the loss of supervision (P = 0.0009) and possible associated costs. Patients considered home treatment more convenient, as it is less time consuming (P = 0.01), and this was perceived as an improvement in quality of life (P = 0.001). It was considered less convenient because it may be unsafe and (or) more expensive.Conclusion: This survey demonstrates that home intravenous therapy maybe the preferred option for patients with antibody deficiency in Ontario, provided this decision was supported by a specialist in the field, secured supervision was available, and it was not associated with personal expenses.Statement of novelty: The first study to examine patient willingness to try a new route of gammaglobulin administration at home.Keywords
This publication has 24 references indexed in Scilit:
- Neither seen nor heard: Children and homecare policy in CanadaSocial Science & Medicine, 2007
- Risks and side effects of therapy with plasma and plasma fractionsBest Practice & Research Clinical Haematology, 2006
- Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insuranceThe European Journal of Health Economics, 2005
- Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at homeJournal of Allergy and Clinical Immunology, 2004
- Subcutaneous immunoglobulin replacement in primary immunodeficienciesClinical Immunology, 2004
- Risks associated with the use of intravenous immunoglobulin 1 1This review article reflects the opinions of the authors and not necessarily those of the U.S. Food and Drug Administration.Transfusion Medicine Reviews, 2003
- Immunoglobulin replacement treatment by rapid subcutaneous infusionArchives of Disease in Childhood, 1998
- Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costsThe Lancet, 1995
- Home treatment of antibody-deficiency syndromes with intravenous immune globulinJournal of Allergy and Clinical Immunology, 1987
- Home intravenous immunoglobulin therapy by self-administrationJournal of Clinical Immunology, 1986